3M Enhances the Emphaze™ AEX Hybrid Purifier
Achieving high product purity early in the manufacturing process and improving efficiency and economics is important to biopharmaceutical manufacturers. Increasing removal of impurities like DNA and HCP during clarification improves the performance of downstream capture and polishing steps. The 3M™ Emphaze™ AEX Hybrid Purifier meet these challenges through reduction of cell debris, DNA and HCP at clarification to help improve downstream process steps. The new Emphaze capsules are sterilization/sanitization compatible and can be used across various aqueous based biopharmaceutical processes, including vaccine purification. Additionally, the improved Emphaze AEX Hybrid Purifier products now feature two new laboratory capsules and one scale-up capsule that allows evaluations at laboratory and scale-up volumes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180905005283/en/
The 3M™ Emphaze™ AEX Hybrid Purifier (Photo: 3M)
“Customer input is critical in evaluating the performance and effectiveness of any product to maximize performance,” said Himanshu Nivsarkar, Global Marketing Manager, 3M Separation and Purification Sciences Division. “With the Emphaze AEX Hybrid Purifier, customers experience benefits in typical monoclonal antibody purification processes, including nominal 30% HCP and greater than 4 log DNA reduction. It has a consistent output turbidity (<5 NTU) leading to potential downsizing of the sterilizing grade membrane and increased product purity post-protein A. This also reduces turbidity post viral inactivation/neutralization step leading to a lower impurities load on the downstream AEX column, thus allowing customers to optimize their processes.”
Emphaze AEX Hybrid Purifier products are synthetic multi-mechanism single-use purifier products used for biopharmaceutical clarification. They deliver consistent, high purity clarified process fluid by removing soluble and insoluble impurities, such as DNA, HCP, and cell debris, through a combination of chromatographic and size exclusion mechanisms. Emphaze AEX Hybrid Purifier products combine three unique 3M technologies — advanced polymer materials, fine fiber nonwovens, and membranes — to deliver a synthetic clarifying product line containing a novel anion exchange nonwoven media and a fine particle, reduction membrane.
For more information, visit 3m.com/bioprocessing
At 3M, we apply science in collaborative ways to improve lives daily. With $32 billion in sales, our 91,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNews.
3M and Emphaze are trademarks of 3M Company.
Emily Sudlow, 612-342-9893
Karwoski & Courage Public Relations
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
GSMA Welcomes Germany’s 5G Spectrum Award, but Cautions against Unnecessary Conditions15.11.2018 11:00 | Tiedote
The GSMA today welcomed the German government’s decision to release the entire 3.4 to 3.8 GHz band (C-Band), essential for the future development of 5G services globally. Making available all of the spectrum in this critical band for 5G, in a timely manner, shows Germany’s commitment to European and global 5G leadership. However, the GSMA warns that some of the currently proposed conditions on the allocation of these vital frequencies may slow Germany’s 5G future. Ultra-fast 5G networks will form the foundation of the world’s digital economy, supporting a wide variety of industry sectors. Imposing unnecessary conditions that limit mobile operators’ ability and potential to deliver 5G creates a risk for all, industries and citizens alike. “The C-Band is the most vital frequency band for 5G. Germany is demonstrating 5G leadership in the timely release of this vital spectrum, but risks undercutting its 5G future with unnecessary obligations,” said Mats Granryd, Director General, GSMA. “Sp
Entersekt Sets Sights on the Nordics15.11.2018 11:00 | Tiedote
Entersekt, an innovator in mobile-first fintech solutions, today announced its entry into the competitive Nordic market. The identity and payments enablement provider serves banks and other enterprises operating in 45 countries. Entersekt’s interest in Scandinavia derives from its openness to digital banking and payments innovation. Digitization may be transforming business in every corner of the world, but few regions have experienced the wholesale change in consumer payments behaviour that the Nordics have. While governments, central banks, and the banking industry as a whole have pushed a cashless agenda for several years now, many point to Nordic consumers’ enthusiastic adoption of cashless transacting as the true driver behind the boom in digital payments. Consumers in the region have never been hidebound to payments innovation, as smart card penetration rates demonstrated years ago. Payments-ready smartphones are, of course, everywhere and the retail NFC infrastructure is superb.
Mobidiag nostaa viimeisen €4M erän Euroopan investointipankin €15M rahoituksesta15.11.2018 09:30 | Tiedote
Mobidiag Oy, vahvassa kasvuvaiheessa oleva molekyylidiagnostiikkayhtiö, joka taistelee antibioottiresistenssin leviämistä vastaan, ilmoitti tänään, että se on nostanut viimeisen 4 miljoonan euron erän 15 miljoonan euron lainasta, jonka Euroopan investointipankki (EIP) myönsi yhtiölle kolmivuotiseen projektiin heinäkuussa 2016. Laina myönnettiin osana EIP:n ”InnovFin - EU Finance for innovators” -ohjelmaa. Ohjelman tavoitteena on tukea innovatiivisten eurooppalaisten yhtiöiden haastavia korkean teknologian kehityshankkeita mahdollistamalla rahoituksen. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20181114005789/fi/ Aiemmin nostettujen EIP:n lainaerien avulla Mobidiag on kehittänyt valmiiksi ja kaupallistanut Novodiag® -molekyylidiagnostiikan järjestelmänsä sekä kaksi suolistoinfektioiden aiheuttajien tunnistamiseen käytettävää testiä (Novodiag® C. difficile ja Novodiag® Bacterial GE+). Viimeisen lainaerän avulla yhtiö nope
European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib15.11.2018 09:30 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx® (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. “Today’s EC approval for the use of Cabometyx ® provides a much needed new option for HCC patients. Until now, physicians in Europe had only one approved therapy for the 2 nd line treatment of this aggressive and difficult-to-treat cancer.1,2 We are proud to offer Cabometyx ® as an innovative treatment that has been shown to extend survival in previously treated patients with HCC,” said Harout Semerjian, Chief Commercial Officer, Ipsen. “This new indication reinforces Ipsen’s commitment to improve patients’ lives through the expansion of the clinical benefit of Cabometyx ® i
Mobidiag Receives Final €4M Tranche of €15M EIB Financing15.11.2018 09:30 | Tiedote
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company from the European Investment Bank Group (EIB) in July 2016. The loan was provided as part of “InnovFin – EU Finance for innovators” programme, an EIB initiative aimed at providing innovative and high quality companies in Europe with access to finance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005786/en/ The EIB funding has already enabled Mobidiag to finalize, launch and commercialize its Novodiag® molecular diagnostic system and two assays for detection of gastrointestinal infections (Novodiag® C. difficile and Novodiag® Bacterial GE+). The final tranche will enable the Company to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system an
Highlights of China’s No. 1 High-Tech Fair CHTF 201815.11.2018 05:00 | Tiedote
The 20th China Hi-Tech Fair (CHTF 2018) is being held from November 14-18 at the Shenzhen Convention and Exhibition Center with the theme “New Development Concept for High Quality Growth.” This year’s CHTF consists of exhibitions, forums, professional meetings, supporting activities, talents exchange meetings and overseas fairs, and features advanced manufacturing, next-generation information technology, AI, life sciences, new materials, new energy, as well as integration of real economy and future industries. Here are some of the highlights of CHTF 2018: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005654/en/ International and Belt & Road Pavilion of CHTF (Photo: Business Wire) Themed areas focusing on industry hotspots The IT exhibition will present themed areas like AI, smart manufacturing, smart automotive, sports technology, big data, cloud computing, IoT and blockchain; the environmental exhibition will highlig
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme